The authors study the results of the combined surgery and postoperative chemotherapy, for treatment of pulmonary metastases. At Léon-Bérard Center, 50 patients have been operated on since 1963. The sites and histologies of the primitive cancers are varied, corresponding to 12 epidermoid cancers, 12 adenocarcinomas, 10 osteogenic sarcomas, 1 Ewing's tumor, 3 malignant melanomas, 6 testicular tumors, and 4 others. The total survival rate is 30% in 4 years. The prognosis is influenced by different factors, which are studied. It depends on the histology of the primitive cancer and the type of the pulmonary excision. It is suggested that postoperative chemotherapy improves the results. It appears that the longer the free interval is between the treatment of the primitive cancer and the discovery of the pulmonary metastasis, the better the prognosis. The correlation between the time lapse of the free interval and the survey after pulmonary excision is studied. The conclusions of the authors are: The association of surgery and chemotherapy improves the results and enforces the indications for surgical excision of pulmonary metastases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jso.2930180202 | DOI Listing |
Cureus
December 2024
Department of Orthopaedics, University of Maryland, Baltimore, USA.
Background: Circulating tumor cells and clusters (CTC) from soft-tissue sarcoma (STS) that become entrapped in the lung can form micro-metastases and lead to pulmonary metastatic disease. Many patients with localized high-risk STS later develop metastases. Radiation is effective at reducing local recurrence by eradicating microscopic infiltration and satellites in the reactive zone surrounding the primary tumor.
View Article and Find Full Text PDFNon-islet cell tumor hypoglycemia (NICTH) is a paraneoplastic syndrome associated with non-mesenchymal-derived and epithelial tumors. A 37-year-old male with stage IVB hepatocellular carcinoma (HCC) and pulmonary metastases presented with recurrent hypoglycemia despite glucose supplementation. Laboratory findings revealed low insulin growth factor 1 (IGF-1) (15 ng/mL), elevated insulin growth factor 2 (IGF-2) (395 ng/ml), and an IGF-2:IGF-1 ratio of 26:1, consistent with NICTH.
View Article and Find Full Text PDFA 79-year-old man was found to have multiple nodules in the lung fields on chest computed tomography. Metastatic lung cancer was suspected; however, the primary site remained elusive. After 1 year of follow-up, both the nodules had enlarged.
View Article and Find Full Text PDFBiol Methods Protoc
December 2024
Medical BioSciences, Radboudumc, Nijmegen 6562 GA, The Netherlands.
Tissue specimens taken from primary tumors or metastases contain important information for diagnosis and treatment of cancer patients. Multiplex imaging allows visualization of heterogeneous cell populations, such as immune cells, in tissue samples. Most image processing pipelines first segment cell boundaries and then measure marker expression to assign cell phenotypes.
View Article and Find Full Text PDFAME Case Rep
January 2025
Department of Oncology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
Background: Treatment options for patients with high-risk metastatic clear cell renal cell carcinoma (mccRCC) include immune checkpoint inhibitors and tyrosine kinase inhibitors (TKIs), but clinical manifestations and treatment of these patients are rarely reported because patients with cardiac metastases and abrupt circulatory disorders are very rare and there are no precise guidelines to follow. In this study, we analyzed and discussed the clinical characteristics, related characteristics, pathogenesis and treatment strategies of patients with cardiac metastases of kidney cancer, so as to provide reference for the diagnosis and treatment of cardiac metastatic tumors.
Case Description: The patient was diagnosed with renal cell carcinoma and underwent surgical radical resection, no special treatment was performed after surgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!